Healthcare provider profile · identity verified

Jini Hae-Jin Han, MD

Internal Medicine · CHICAGO, IL · NPI 1669404240

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	526	155
Amlodipine Besylate	Amlodipine Besylate	523	155
Pravastatin Sodium	Pravastatin Sodium	368	103
Levothyroxine Sodium	Levothyroxine Sodium	312	81
Losartan Potassium	Losartan Potassium	251	74
Metoprolol Succinate	Metoprolol Succinate	241	65
Rosuvastatin Calcium	Rosuvastatin Calcium	170	51
Lisinopril	Lisinopril	122	35
Hydrochlorothiazide	Hydrochlorothiazide	116	34
Sertraline Hcl	Sertraline Hcl	116	35
Famotidine	Famotidine	115	40
Omeprazole	Omeprazole	112	41
Synthroid	Levothyroxine Sodium	101	21
Metformin Hcl	Metformin Hcl	89	26
Simvastatin	Simvastatin	86	29
Fluticasone Propionate	Fluticasone Propionate	85	30
Gabapentin	Gabapentin	80	27
Albuterol Sulfate Hfa	Albuterol Sulfate	61	38
Alprazolam	Alprazolam	61	24
Pantoprazole Sodium	Pantoprazole Sodium	60	20
Zolpidem Tartrate	Zolpidem Tartrate	54	28
Metformin Hcl Er	Metformin Hcl	51	14
Carvedilol	Carvedilol	50	16
Escitalopram Oxalate	Escitalopram Oxalate	47	14
Atenolol	Atenolol	44	12
Azelastine Hcl	Azelastine Hcl	38	15
Eliquis	Apixaban	37	14
Lorazepam	Lorazepam	37	21
Fluoxetine Hcl	Fluoxetine Hcl	36	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	36	36
Azithromycin	Azithromycin	34	33
Furosemide	Furosemide	34	14
Clopidogrel	Clopidogrel Bisulfate	33	suppressed
Ezetimibe	Ezetimibe	31	13
Glipizide Er	Glipizide	31	suppressed
Ketoconazole	Ketoconazole	30	15
Tamsulosin Hcl	Tamsulosin Hcl	29	12
Trazodone Hcl	Trazodone Hcl	29	12
Tramadol Hcl	Tramadol Hcl	28	suppressed
Irbesartan	Irbesartan	26	suppressed
Montelukast Sodium	Montelukast Sodium	26	suppressed
Estradiol	Estradiol	25	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	23	20
Ramipril	Ramipril	23	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	22	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Valsartan	Valsartan	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	13
Bupropion Xl	Bupropion Hcl	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	18	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Ipratropium Bromide	Ipratropium Bromide	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	16	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	15	suppressed
Diazepam	Diazepam	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Alendronate Sodium	Alendronate Sodium	13	suppressed
Azelastine-Fluticasone	Azelastine/Fluticasone	13	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Celecoxib	Celecoxib	12	suppressed
Glimepiride	Glimepiride	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Allopurinol	Allopurinol	11	suppressed
Premarin	Estrogens, Conjugated	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error